Is SRPT a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Sarepta Therapeutics (SRPT) rests on Elevidys franchise durability: Elevidys was the largest growth driver before the safety events, and its trajectory now hinges on a narrower label focused on ambulatory patients plus prescriber and payer confidence. 2026 revenue guidance is ~$1.2B-$1.4B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage. Whether SRPT is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Sarepta Therapeutics is a biotechnology company focused almost entirely on Duchenne muscular dystrophy (DMD), a fatal muscle-wasting genetic disease. Its portfolio has two pillars: Elevidys (delandistrogene moxeparvovec), the first approved gene therapy for DMD delivered with the AAVrh74 viral vector, and an older RNA-based exon-skipping franchise (Exondys 51, Vyondys 53, Amondys 45) that treats subsets of patients by helping cells skip faulty sections of the dystrophin gene. Roche holds ex-US commercialization rights to Elevidys, which produces meaningful licensing and royalty revenue for Sarepta. The company reiterated 2026 net product revenue guidance of roughly $1.2 billion to $1.4 billion. The investment picture in mid-2026 is defined by a severe safety and regulatory shock. In 2025 Sarepta reported multiple patient deaths from acute liver failure tied to its AAVrh74 gene-therapy vector, the FDA added a boxed warning, revoked the platform technology designation, requested a shipment halt, and placed a related trial on clinical hold. The company cut about 36 percent of its workforce (roughly 500 employees) and restructured to target around $400 million in annualized savings and self-fund its pipeline. Market capitalization fell from over $11 billion in early 2025 to roughly $2 billion by mid-2026, so the stock now reflects deep uncertainty about Elevidys adoption alongside a still-profitable base RNA business.
What's the case for buying SRPT?
1. Elevidys franchise durability
Elevidys was the largest growth driver before the safety events, and its trajectory now hinges on a narrower label focused on ambulatory patients plus prescriber and payer confidence. Sarepta resumed shipments to ambulatory patients in the US after halting broader distribution. Whether revenue stabilizes or keeps eroding is the single biggest swing factor for the stock.
2. Cash-generative base RNA business
The older exon-skipping drugs (Exondys 51, Vyondys 53, Amondys 45) remain approved and revenue-generating, and the company reported the base business produced over $330 million of positive cash flow in 2025. This established franchise gives Sarepta a revenue floor independent of gene-therapy headlines and helps fund the pipeline.
3. Restructuring and self-funding
The 36 percent workforce reduction targets roughly $400 million in annualized savings and a 2026 non-GAAP expense outlook of about $800 million to $900 million. Management has emphasized reaching a self-funded position, with cash and investments reported around $748 million. Cost discipline is meant to preserve optionality while the top line resets.
4. Next-generation pipeline and Roche partnership
Sarepta continues to develop next-generation approaches (including PPMO and additional gene-therapy programs) and collects ex-US economics from Roche on Elevidys. Cohort readouts and pipeline data points are potential catalysts, though several programs sit under heightened FDA scrutiny after the vector-safety events.
What are the risks to SRPT?
The defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage. Regulatory posture toward Elevidys and future gene therapies is uncertain and could further narrow labels or restrict use. Sarepta is heavily concentrated in a single disease (DMD), so a franchise setback has outsized impact. Competition is intensifying from Dyne Therapeutics, Avidity Biosciences, REGENXBIO, Pfizer, and Solid Biosciences, several of which could reach the market in 2026-2027. As a biotech that has cut a third of its staff amid falling revenue, execution, litigation exposure, and financing risk all remain elevated.
How is SRPT valued? (as of JULY 2026)
Snapshot for SRPT as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Market cap: ~$2.1B
- 2026 revenue guidance: ~$1.2B-$1.4B
- Cash & investments: ~$748M
- 2026 non-GAAP expense outlook: ~$800M-$900M
- 2025 base-business cash flow: ~$330M+
- Workforce reduction: ~36% (~500 roles)
SRPT's market cap fell roughly 80 percent from over $11 billion in early 2025 to around $2 billion by mid-2026 as the Elevidys safety events reset expectations. The company remains a real revenue-generating biotech with reiterated 2026 net product revenue guidance of roughly $1.2 billion to $1.4 billion and a cash cushion. Valuation now reflects deep uncertainty about gene-therapy adoption rather than a going-concern question about the base RNA business.
How do you decide if SRPT is a buy?
Rather than asking whether SRPT is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold SRPT indirectly through an index or sector ETF before adding more.
For the full picture, see the SRPT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about SRPT against your real portfolio and see your actual exposure before deciding.
The bottom line on SRPT
The bottom line: Sarepta Therapeutics's story right now is Elevidys franchise durability, with 2026 revenue guidance at ~$1.2B-$1.4B. If you believe that narrative continues, the call is about sizing SRPT sensibly and checking overlap with what you own; if you doubt it (the risk: the defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around SRPT with Walnut
Use Sarepta Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is SRPT a good stock to buy right now?
+
The case for Sarepta Therapeutics right now is Elevidys franchise durability, with 2026 revenue guidance at ~$1.2B-$1.4B. If you believe that thesis holds, SRPT is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Sarepta Therapeutics do?
+
Sarepta Therapeutics is a biotechnology company focused almost entirely on Duchenne muscular dystrophy (DMD), a fatal muscle-wasting genetic disease.
What are the main risks of SRPT?
+
The defining risk is safety: multiple patient deaths from acute liver failure linked to the AAVrh74 vector led to a boxed warning, loss of platform technology designation, a shipment halt, and a clinical hold, and any further adverse events could deepen the damage. Regulatory posture toward Elevidys and future gene therapies is uncertain and could further narrow labels or restrict use. Sarepta is heavily concentrated in a single disease (DMD), so a franchise setback has outsized impact. Competition is intensifying from Dyne Therapeutics, Avidity Biosciences, REGENXBIO, Pfizer, and Solid Biosciences, several of which could reach the market in 2026-2027. As a biotech that has cut a third of its staff amid falling revenue, execution, litigation exposure, and financing risk all remain elevated.
What does Sarepta Therapeutics do?
+
Sarepta is a rare-disease biotech focused on Duchenne muscular dystrophy. It sells Elevidys, a gene therapy, and a set of older RNA-based exon-skipping drugs (Exondys 51, Vyondys 53, Amondys 45) that treat specific genetic subsets of DMD patients.
What is Elevidys?
+
Elevidys (delandistrogene moxeparvovec) is Sarepta's gene therapy for DMD, delivered using the AAVrh74 viral vector. It was the company's largest growth product before 2025-2026 safety events narrowed its label and disrupted distribution.
What happened with the Elevidys patient deaths?
+
In 2025 Sarepta reported multiple patient deaths from acute liver failure associated with its AAVrh74 gene-therapy vector, including cases tied to Elevidys and a separate trial. The events triggered a boxed warning, loss of FDA platform designation, a shipment halt, and a clinical hold.
Is Sarepta still selling Elevidys?
+
Sarepta resumed shipments of Elevidys to ambulatory patients in the US after halting broader distribution, operating under a narrower label. The durability of that revenue is a central uncertainty for the company.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell SRPT; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.